Forte Biosciences (FBRX) Operating Margin (2017 - 2019)
Forte Biosciences (FBRX) posted quarterly Operating Margin of 17377.78% for Q4 2019, up 19493333.0% year-over-year from N/an in Q4 2018, and down 128.65% quarter-over-quarter from 7600.0% in Q3 2019.
Forte Biosciences (FBRX) Operating Margin (2017 - 2019) Analysis & Trends
Forte Biosciences (FBRX) has reported Operating Margin for 3 consecutive years, with 17377.78% the latest figure, recorded in Q4 2019.
- In Q4 2019, Operating Margin rose 19493333.0% year-over-year to 17377.78%; the TTM figure through Dec 2019 stood at 54855.56% (down 5460132.0% YoY), while the FY2019 annual figure was 11288.89%, down 1103466.0% from the prior year.
- Operating Margin retreated to 17377.78% in Q4 2019 per FBRX's latest filing, from 7600.0% in the prior quarter.
- Across five years, Operating Margin topped out at 7.92% in Q3 2018 and bottomed at 212311.11% in Q4 2018.
- Historically, Operating Margin has averaged 94138.07% across 3 years, with a median of 97370.0% in 2017.
- Annual changes were most pronounced in 2018 — Operating Margin tumbled 10544111 bps — and 2019, when it surged 19493333 bps.
- Forte Biosciences' Operating Margin stood at 106870.0% in 2017, then tumbled by 99 bps to 212311.11% in 2018, then soared by 92 bps to 17377.78% in 2019.
- Business Quant data shows FBRX's Operating Margin at 17377.78% in Q4 2019, 7600.0% in Q3 2019, and 6988.89% in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -105.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Forte Biosciences | 1.63 Bn | 1.28 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | -17,377.78% |
| Sep 30, 2019 | -7,600.00% |
| Jun 30, 2019 | -6,988.89% |
| Mar 31, 2019 | -187,455.56% |
| Dec 31, 2018 | -212,311.11% |
| Sep 30, 2018 | 7.92% |
| Jun 30, 2018 | -170,300.00% |
| Mar 31, 2018 | -142,733.33% |
| Dec 31, 2017 | -106,870.00% |
| Sep 30, 2017 | -97,370.00% |
| Jun 30, 2017 | -86,520.00% |